Copyright
©2014 Baishideng Publishing Group Inc.
World J Hepatol. Nov 27, 2014; 6(11): 818-824
Published online Nov 27, 2014. doi: 10.4254/wjh.v6.i11.818
Published online Nov 27, 2014. doi: 10.4254/wjh.v6.i11.818
HCC (n = 30) | Cirrhosis (n = 30) | CH (n = 30) | Normal (n = 10) | P value | |
Age (yr) Mean ± SD | 60.27 ± 8.20C | 55.07 ± 7.35B | 38.20 ± 8.21A | 40.89 ± 16.85A | ≤ 0.001 |
Gender (male) | 25 (83.3) | 21 (70) | 22 (73.3) | 6 (66.7) | 0.6 |
Hb (g/dL ) | 11.44 ± 2.85B | 10.53 ± 2.00B | 14.23 ± 1.58A | 14.03 ± 2.48A | < 0.001 |
WBC × 103/mm3 | 5.73 ± 2.56A | 7.08 ± 3.77A | 6.15 ± 2.13A | 7.38 ± 2.72A | 0.217 |
Platelets 10/mm3D | 126.00 ± 74.05B | 116.10 ± 68.94B | 228.80 ± 59.74A | 271.3 ± 116.7A | < 0.001 |
Total bilirubin (0.1-1.2 mg/dL) | 1.88 ± 2.01A | 4.29 ± 6.75B | 0.74 ± 0.26A | 0.79 ± 0.36A | < 0.001 |
ALT (0-42 IU/L) | 66.59 ± 44.59B | 32.15 ± 23.59A | 66.78 ± 36.56B | 29.16 ± 19.96A | < 0.001 |
AST (0-42 IU/L) | 119.99 ± 56.12B | 63.81 ± 39.49A | 59.67 ± 45.04A | 45.64 ± 54.32A | < 0.001 |
ALP (0-290 IU/L)D | 394.8 ± 282.28A | 304.89 ± 191.85A | 203.58 ± 82.37AB | 198.8 ± 139.1B | 0.003 |
Albumin (3.5-5.5 g/dL)D | 3.16 ± 0.40C | 2.49 ± 0.54B | 4.22 ± 0.36A | 4.09 ± 0.92A | < 0.001 |
PC % | 69.63 ± 16.25C | 51.58 ± 17.12B | 88.24 ± 10.89A | 97.63 ± 11.77A | < 0.001 |
AFP log10 ng/dL | 2.50 ± 1.19B | 0.79 ± 0.54A | 0.59 ± 0.38A | NA | < 0.001 |
Parameter | Number (%) | |
AFP level (0-10) | Normal | 4 (13.4%) |
Elevated | 26 (86.6%) | |
PS | PS 0 | 24 (80) |
PS 1-2 | 4 (13.4) | |
PS > 2 | 2 (6) | |
BCLC | Stage 0 | 0 (0) |
Stage A | 1 (3.8) | |
Stage B | 19 (73.1) | |
Stage C | 4 (15.4) | |
Stage D | 2 (7.7) | |
Number of focal lesions | Single | 17 (56.7) |
Multiple | 13 (43.4) | |
Site of focal lesions | Right lobe | 18 (60) |
Left lobe | 5 (16.7) | |
Both | 7 (23.3) | |
Tumor size by CT | < 3 cm | 1 (3.3) |
3-5 cm | 12 (40) | |
> 5 cm | 17 (56.7) | |
Portal vein invasion | Yes | 7 (23.3) |
No | 23 (76.7) |
AUC | P value | Best cutoff | Sensitivity | Specificity | PPV | NPV |
0.655 | 0.03 | < 1.82 | 0.87 | 0.40 | 0.47 | 0.83 |
- Citation: El-Garem H, Ammer A, Shehab H, Shaker O, Anwer M, El-Akel W, Omar H. Circulating microRNA, miR-122 and miR-221 signature in Egyptian patients with chronic hepatitis C related hepatocellular carcinoma. World J Hepatol 2014; 6(11): 818-824
- URL: https://www.wjgnet.com/1948-5182/full/v6/i11/818.htm
- DOI: https://dx.doi.org/10.4254/wjh.v6.i11.818